Equitec Proprietary Markets’s Sage Therapeutics SAGE Stock Holding History

Equitec Proprietary Markets’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-63,900	Closed	-$583K	–	94
2025 Q2	$583K	Buy	+63,900	New	+$470K	0.55%	21

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Equitec Proprietary Markets's SAGE Position: Q3 2025 in Review

Equitec Proprietary Markets sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 63,900 shares — an estimated $583K sold.

Equitec Proprietary Markets first reported a position in SAGE in Q2 2025 and held it in 1 quarter. The position peaked at $583K in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Equitec Proprietary Markets reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Equitec Proprietary Markets sold 63,900 Sage Therapeutics shares in Q3 2025, an estimated $583K.
Equitec Proprietary Markets first reported a position in Sage Therapeutics in Q2 2025 and held it in 1 quarter.
Equitec Proprietary Markets's Sage Therapeutics position peaked at $583K in Q2 2025.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Equitec Proprietary Markets's 13F filing for Q3 2025, filed 26 Nov 2025.